Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study
Year: 2020
Type: article
Study design: Observational Study
Abstract: To the Editor, The detection of anti-SARS-CoV-2 antibodies is valuable to improve the sensitivity of pathogenic diagnosis for COVID-19, to identify convalescent plasma donors, to screen the population to determine the seroprevalence and to assess the persistence of protection in the population or at the individual level [1-3].A wide range of serology immunoassays have been developed to complement the RT-PCR, with different SARS-CoV-2 antigen targets and formats [4].Due to the widespread dissemination of these methods and the limited experience with these new assays, it is crucial for laboratories to rigorously validate these methods before broad introduction into routine clinical practice [1,3,5].Recently, the performances of the Elecsys assay have been published.The Elecsys anti-SARS-CoV-2 is an electrochemiluminescent immunoassay (ECLIA) for the in vitro qualitative detection of total antibodies, including IgG, to SARS-CoV-2 in human serum and plasma.The assay uses a recombinant protein representing the nucleocapsid antigen for the determination of antibodies against SARS-CoV-
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3041663063